Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 4, 2013, Pages 845-852

  Song, Hunho ^a   Han, Boram ^a   Park, Choong Kee ^a   Kim, Jong Hyeok ^a   Jeon, Jang Yong ^a   Kim, In Gyu ^a   Kim, Hyo Jung ^a   Jung, Joo Young ^a   Kim, Jung Han ^a   Kwon, Jung Hye ^a   Jang, Geundoo ^a   Kim, Ho Young ^a   Kim, Hyeong Su ^a   Choi, Dae Ro ^a   Zang, Dae Young ^a  

^a Hallym University Medical Center   (South Korea)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer; S 1

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CYTOLOGY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OXONIC ACID; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 84885376361     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2265-z     Document Type: Article

References (26)

1. Annual report of cancer statistics in Korea in 2009. National Cancer Control Institute
2. Mancuso A, Calabrò F, Sternberg CN (2006) Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 58:231-241
3. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line chemotherapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15:2403-2413
4. Ozaka M, Matsumura Y, Ishii H et al (2012) Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 69:1197-1204
5. Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275
6. Colucci G, Giuliani F, Gebbia V et al (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic cancer. Cancer 94:902-910
7. Louvet C, André T, Lledo G et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512-1528
8. Moore MJ, Goldstein D, Hamm J, National Cancer Institute of Canada Clinical Trial Group et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 25:1960-1966
9. Shirasaka T, Nakano K, Takechi T et al (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602-2606
10. Okusaka T, Funakoshi A, Furuse J et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615-621
11. Ueno H, Okusaka T, Ikeda M et al (2005) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68:171-178
12. Nakamura K, Yamaguchi T, Ishihara T et al (2005) Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 92:2134-2139
13. Nakamura K, Yamaguchi T, Ishihara T et al (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94:1575-1579
14. Ren Q, Kao V, Grem JL (1998) Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 4(11):2811-2818
15. Hidalgo M, Castellano D, Paz-Ares L et al (1999) Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585-592
16. Scheithauer W, Schüll B, Ulrich-Pur H et al (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14:97-104
17. Stathopoulos GP, Syrigos K, Polyzos A et al (2004) Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 15(2):224-229
18. Nakai Y, Isayama H, Sasaki T et al (2010) Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol 40:774-780
19. Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 1:1640-1648
20. Oh DY, Cha Y, Choi IS et al (2010) A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol 65:527-536
21. Kim MK, Lee KH, Jang BI et al (2009) S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 39:49-53
22. Ueno H, Okusaka T, Furuse J et al (2011) Multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol 41:953-958
23. Nakai Y, Isayama H, Sasaki T et al (2012) A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 106:1934-1939
24. Inal A, Kos FT, Algin E, Anatolian Society of Medical Oncology et al (2012) Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. J BUON 17:102-105
25. Yi JH, Lee J, Park SH et al (2011) A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology 80:175-180
26. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825